Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Freedom Finance and Binance Join Forces in Digital Assets 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
SAN CARLOS, Calif., May 03, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2995797. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/ouykqu6a.
A replay of the call will be available from May 10, 2018 at 7:30 p.m. ET to May 17, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 2995797. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
